Accordingly, neutralizing antibodies that target the extracellular domain of EGFR (e.g. cetuximab) have sporadically shown clinical efficacy in advanced cholangiocarcinoma (Paule et al., 2007). Here, EGFR is linked to cholangiocarcinoma.